-
TCC, Human, mAb aE11, FITC
TCC, Human, mAb aE11, FITC
- 中文名称：
- TCC, Human, mAb aE11, FITC
- 英文名称：
- TCC, Human, mAb aE11, FITC
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA77779
- 规格：
- 0.1 mg|2x0.1 mg|3x0.1 mg|4x0.1 mg|5x0.1 mg
- 保存建议：
- Product should be stored at 4 degree C. Under recommended storage conditions, product is stable for at least one year.
- 货期：
- 6-8周
- 来源宿主：
- Mouse
- 反应种属：
- Horse: Yes; Swine: Yes
- 应用：
- IHC (Immunohistochemistry), IF (Immunofluorescence), IA (Immunoassay), FA (Functional Assay), FCM/FACS (Flow Cytometry)
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 其他：
克隆性:Monoclonal
同型:Mouse IgG2a
克隆号:[aE11]
特异性:N/A
纯度:Protein G
形式：0.2 um filtered in PBS+1%BSA+0.02%NaN3
浓度：100 ug/ml
- 说明书：
Product Description: Monoclonal antibody aE11 reacts with a C9 neoantigen of the terminal complement complex (TCC). The three distinct activation pathways of complement converge with the formation of a C5 convertase. The cleavage of C5 by this convertase initiates the lytic or terminal pathway. In contrast to the activation pathways, which require enzymatic cleavage for activation, the terminal pathway relies on conformational changes induced by binding. Binding of C6 facilitates binding of C7 which alters the conformation of the complex. After binding of C8, a variable number of C9 molecules associate with the C5b678 complex, which is also termed- the terminal complement complex (TCC). The formation of TCC causes lysis of cells or can trigger a variety of cellular metabolic pathways resulting in the synthesis and release of inflammatory mediators. The TCC contains neoantigens that are absent from the individual native components.- C9 neoantigens are present both in the membrane-bound (MAC) and the fluid-phase (SC5b-9) complex. TCC is present in normal human plasma and increased in patients with complement activation.
